Carnegie acted as joint bookrunner in the directed new share issue of 1,675,162 new shares at a subscription price of SEK 73 per share. Xspray Pharma AB is a pharmaceutical development company with several product candidates in clinical development. Xspray employs a patent protected technology platform to develop improved and generic versions of already marketed drugs, primarily protein kinase inhibitors (PKIs) for targeted cancer treatment. December 2019.
Healthcare
Directed new share issue in Xspary Pharma AB (SE) — SEK 122 million
December 2019